Overview

* Nurix Q3 revenue falls to $7.9 mln, down from $12.6 mln last year

* Net loss for Q3 was $86.4 mln, missing analyst expectations

* Research and development expenses rose to $86.1 mln, driven by clinical trial costs

Outlook

* Nurix plans pivotal trials for bexobrutideg in H2 2025

* Company to provide clinical updates for bexobrutideg

* Nurix advancing autoimmune drug pipeline with Gilead and Sanofi

Result Drivers

* BEXOBRUTIDEG TRIALS - Nurix plans pivotal trials for bexobrutideg in relapsed/refractory CLL patients in H2 2025, aiming for accelerated approval

* GS-6791 PRECLINICAL DATA - Presented data at EADV 2025 showing GS-6791's efficacy

* R&D EXPENSES - Increase in R&D expenses due to accelerated enrollment and preparation for pivotal trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$1.03

Q3 Net Miss -$86.42 -$72.30

Income mln mln (16

Analysts

)

Q3 Miss -$91.38 -$78.20

Income mln mln (15

from Analysts

Operatio )

ns

Q3 Miss -$86.42 -$72.60

Pretax mln mln (14

Profit Analysts

)

Q3 Basic -$1.03

EPS

Q3 $99.27

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Nurix Therapeutics Inc ( NRIX ) is $30.50, about 67.3% above its October 8 closing price of $9.98

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)